What happened, in summary

A 67-year-old woman was diagnosed in late 2021 with adenocarcinoma of the left upper lung after several months of neck, shoulder, and arm pain. The cancer had already spread to the cervical and lumbar spine, making it Stage IV. Molecular testing found EGFR and TP53 mutations. She started osimertinib, and follow-up CT scans showed a substantial reduction in the lung lesions. She then received radiation therapy from June through August 2022. Later that year, she developed cough, shortness of breath, and several serious lung infections in the setting of prior radiation-related lung injury. In December 2022 she was hospitalized again and subsequently developed severe COVID-19. Her care focused on the infection and damaged lungs, including antiviral and supportive treatment and mesenchymal stem-cell therapy for the severe lung illness. She recovered sufficiently to leave the hospital and was still alive at the last follow-up in July 2023. The latest cancer-specific information in the narrative continued to show the earlier marked response to osimertinib.